Item 7.01  Regulation FD Disclosure.
On June 4, 2021, Genocea Biosciences, Inc. issued a press release announcing
long-term immunogenicity and clinical response data from its GEN-009 neoantigen
vaccine Phase 1 clinical trial. A copy of the press release, dated June 4, 2021,
is attached to this Current Report on Form 8-K as Exhibit 99.1 and is
incorporated herein by reference.
The information contained in this Item 7.01 of this Current Report on Form 8-K,
including the exhibits attached hereto, is being furnished and shall not be
deemed "filed" for any purpose, and shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, regardless of any general
incorporation language in any such filing.
Item 9.01  Financial Statements and Exhibits.
(d) Exhibits
    Exhibit Number           Exhibit Description
         99.1                  Press release issued by Genocea Biosciences, Inc. on June 4, 2021
         104                 Cover Page Interactive Data File (embedded within the Inline XBRL
                             document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses